Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors

Buckway, Brandon; Wang, Yongjian; Ray, Abhijit; Ghandehari, Hamidreza

doi:10.1016/j.ijpharm.2013.07.067

Cited by 28 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12][13] Single-positron emission computed tomography/computed tomography studies showed that radioconjugated peptides were able to accumulate specifically at the tumor site, with K d ranging from 30 to 45 nM, with minimal nonspecific retention in other organs. This peptide sequence has also been proposed for the selective delivery of supramolecular carriers such as copolymeric micelles 14 or pH-tunable liposomes 15 for diagnostic or therapeutic applications.…”

Section: Ringhieri Et Almentioning

confidence: 99%

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells

Ringhieri¹,

Mannucci²,

Conti³

et al. 2017

IJN

View full text Add to dashboard Cite

Mixed liposomes, obtained by coaggregation of 1,2-dioleoyl-sn-glycero-3-phosphocholine and of the synthetic monomer containing a gadolinium complex ([C18]2DTPA[Gd]) have been prepared. Liposomes externally decorated with KCCYSL (P6.1 peptide) sequence in its monomeric, dimeric, and tetrameric forms are studied as target-selective delivery systems toward cancer cells overexpressing human epidermal growth factor receptor-2 (HER-2) receptors. Derivatization of liposomal surface with targeting peptides is achieved using the postmodification method: the alkyne-peptide derivative Pra-KCCYSL reacts, through click chemistry procedures, with a synthetic surfactant modified with 1, 2, or 4 azido moieties previously inserted in liposome formulation. Preliminary in vitro data on MDA-MB-231 and BT-474 cells indicated that liposomes functionalized with P6.1 peptide in its tetrameric form had better binding to and uptake into BT-474 cells compared to liposomes decorated with monomeric or dimeric versions of the P6.1 peptide. BT-474 cells treated with liposomes functionalized with the tetrameric form of P6.1 showed high degree of liposome uptake, which was comparable with the uptake of anti-HER-2 antibodies such as Herceptin. Moreover, magnetic MRI experiments have demonstrated the potential of liposomes to act as MRI contrast agents

show abstract

Section: Ringhieri Et Almentioning

confidence: 99%

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells

Ringhieri¹,

Mannucci²,

Conti³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Despite high bone uptake, insufficient distribution of the delivery system to soft tissues was observed which might cause substantial in vivo side effects and therefore further optimization of the conjugation strategy would be required before this approach can be translated to clinical settings. In a different study, Buckway et al reported the synthesis of 111 In-labeled HPMA copolymers conjugated with short peptide sequences targeting pancreatic tumors (43). The authors used cyclic RGD (cRGD) peptide and KCCYSL peptide to target integrin α v β 3 expression and HER2 receptors, respectively.…”

Section: Carriers For Spect-igddmentioning

confidence: 99%

Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature

Chakravarty

Hong²,

Cai³

2015

CDT

View full text Add to dashboard Cite

Tremendous resources are being invested all over the world for prevention, diagnosis, and treatment of various types of cancer. Successful cancer management depends on accurate diagnosis of the disease along with precise therapeutic protocol. The conventional systemic drug delivery approaches generally cannot completely remove the competent cancer cells without surpassing the toxicity limits to normal tissues. Therefore, development of efficient drug delivery systems holds prime importance in medicine and healthcare. Also, molecular imaging can play an increasingly important and revolutionizing role in disease management. Synergistic use of molecular imaging and targeted drug delivery approaches provides unique opportunities in a relatively new area called `image-guided drug delivery' (IGDD). Single-photon emission computed tomography (SPECT) is the most widely used nuclear imaging modality in clinical context and is increasingly being used to guide targeted therapeutics. The innovations in material science have fueled the development of efficient drug carriers based on, polymers, liposomes, micelles, dendrimers, microparticles, nanoparticles, etc. Efficient utilization of these drug carriers along with SPECT imaging technology have the potential to transform patient care by personalizing therapy to the individual patient, lessening the invasiveness of conventional treatment procedures and rapidly monitoring the therapeutic efficacy. SPECT-IGDD is not only effective for treatment of cancer but might also find utility in management of several other diseases. Herein, we provide a concise overview of the latest advances in SPECT-IGDD procedures and discuss the challenges and opportunities for advancement of the field.

show abstract

“…Buckway et al used traditional animal model of pancreatic cancer and demonstrated that tumor targeting could be achieved when co-adminstering hyaluronidase [159]. However, decisive experiments to prove the suitability of this approach for macromolecular therapeutics will be those using genetically engineered mouse models and combination treatment including hyaluronidase and/or hedgehog pathway inhibitors.…”

Section: Water-soluble Polymer-drug Conjugatesmentioning

confidence: 99%

Macromolecular therapeutics

Yang

Kopeček

2014

Journal of Controlled Release

View full text Add to dashboard Cite

This review covers water-soluble polymer-drug conjugates and macromolecules that possess biological activity without attached low molecular weight drugs. The main design principles of traditional and backbone degradable polymer-drug conjugates as well as the development of a new paradigm in nanomedicines – (low molecular weight) drug-free macromolecular therapeutics are discussed. To address the biological features of cancer, macromolecular therapeutics directed to stem/progenitor cells and the tumor microenvironment are deliberated. Finally, the future perspectives of the field are briefly debated.

show abstract

Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors

Cited by 28 publications

References 46 publications

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells

Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature

Macromolecular therapeutics

Contact Info

Product

Resources

About